Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CervoMed Reports Ph2b Data On Neflamapimod In Lewy Body Dementia
    CervoMed Reports Ph2b Data On Neflamapimod In Lewy Body Dementia

    08 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/08/3163184/0/en/CervoMed-Announces-New-Data-from-Phase-2b-Trial-Demonstrating-Neflamapimod-s-Potential-as-a-Treatment-for-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    08 Oct 2025
    Share Share
    CervoMed Showcases Neflamapimod Benefits for Lewy Body Dementia
    CervoMed Showcases Neflamapimod Benefits for Lewy Body Dementia

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151536/0/en/CervoMed-Highlights-Neflamapimod-s-Potential-Benefits-in-Session-on-Dementia-with-Lewy-Bodies-at-the-150th-Annual-American-Neurology-Association-Conference.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share
    CervoMed: RewinD-LB Trial Shows Neflamapimod Slows Dementia
    CervoMed: RewinD-LB Trial Shows Neflamapimod Slows Dementia

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122322/0/en/CervoMed-Announces-32-Week-Data-from-RewinD-LB-Trial-Extension-Phase-Showing-Neflamapimod-s-Sustained-Effect-on-Slowing-Clinical-Progression-in-Patients-with-Dementia-with-Lewy-Bod.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    CervoMed Announces Presentations at Alzheimer’s Congress 2025
    CervoMed Announces Presentations at Alzheimer’s Congress 2025

    08 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/08/3111598/0/en/CervoMed-Announces-Late-Breaking-Presentations-at-Alzheimer-s-Association-International-Congress-2025.html

    GLOBENEWSWIRE
    08 Jul 2025
    Share Share
    CervoMed Hires to Support Neflamapimod Development
    CervoMed Hires to Support Neflamapimod Development

    10 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/10/3096571/0/en/CervoMed-Announces-New-Hire-to-Support-Neflamapimod-Development-and-Commercialization.html

    GLOBENEWSWIRE
    10 Jun 2025
    Share Share
    Neflamapimod Slow Dementia Progression in Lewy Bodies at AD/PD 2025
    Neflamapimod Slow Dementia Progression in Lewy Bodies at AD/PD 2025

    02 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/02/3054108/0/en/Investigators-to-Present-Clinical-Trial-Results-Showing-Neflamapimod-Slows-Clinical-Progression-in-Dementia-with-Lewy-Bodies-in-Oral-Presentation-at-AD-PD-2025.html

    GLOBENEWSWIRE
    02 Apr 2025
    Share Share